In 2025, the American Cancer Society reports that prostate cancer remains the most common cancer among men in the U.S., with an estimated 313,780 new cases and 35,770 deaths (Cancer Facts & Figures, ACS 2025) and the prevalence is more than 3.5 million men living with prostate cancer in the U.S. ( SEER*Explorer)
Although treatment options for patients presenting with organ-confined cancers have improved the 5-year survival of patients, treatment failure, resistance to systemic therapies and disease progression account for the majority of cancer deaths. Furthermore, treatment with chemotherapy agents, such as taxanes and PARP inhibitors, is associated with dose dependent hematological, cardiac, pulmonary and neurological toxicities.
Precision medicine targeting such drugs to PSMA-expressing prostate cancers offers to optimize drug delivery to the cancer cells to lessen effects on non-cancerous tissues, potentially leading to improved clinical outcomes.
At Prostate Theranostics (PTX), we are dedicated to improving the lives of patients with advanced prostate cancer through the development of prostate specific membrane antigen (PSMA)-targeted diagnostic and therapeutic technologies.